Triple drug therapy before surgery for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of three targeted drugs (olaparib, durvalumab, and bevacizumab) as a first treatment for advanced ovarian cancer. It aims to shrink tumors before possible surgery, potentially improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer has not been treated with chemotherapy yet.
- Your cancer is stage IV and surgery is not planned right away, but may be possible later if the tumor shrinks.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are at least 18 years old and have good overall health (ECOG performance status 0 or 1).
- You do not have a known BRCA gene mutation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, bevacizumab, and chemotherapy given before surgery for advanced ovarian cancer. The goal is to shrink tumors to make surgery more effective and potentially improve outcomes.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
This trial tests a combination of two immunotherapy drugs with chemotherapy, with or without a targeted therapy pill, given before surgery for advanced ovarian cancer. It aims to shrink tumors to make surgery more effective and potentially improve outcomes.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests two oral medications, pamiparib and surufatinib, given before surgery to shrink advanced ovarian cancer. The goal is to make surgery more successful and potentially improve outcomes for patients who cannot have surgery right away.
Hear when a new Ovarian Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.